To this aim, we retrospectively evaluated data collected from our archives of advanced stage NSCLC patients with positive PD-L1 expression (≥1%) who were referred to our clinic for evaluation of at least five of the most common driver mutations, namely, EGFR, KRAS, BRAF, ALK and ROS1. Here, ALK is linked to non-small cell lung carcinoma.